Literature DB >> 18440102

Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes.

Indresh Srivastava1, Amanda Goodsell, Fengmin Zhou, Yi Sun, Brian Burke, Susan Barnett, Michael Vajdy.   

Abstract

In this study, immunizations at 2 weeks vs. 6 weeks intervals, with an HIV-1 envelope protein in adjuvants, through intra-nasal (IN), intra-muscular (IM), IN followed by IM (IN/IM) and IM/IN, were compared for induction of mucosal and systemic immune responses. IN/IM immunizations at 2, but not at 6, week intervals induced the highest mucosal and systemic immune responses compared to other immunization routes. Following a resting memory phase, IN boosting of IN/IM-immunized mice, compared to IM-boosting of IM-immunized mice, induced increased IgA responses. Thus, depending on the immunization intervals, IN/IM may be more effective than IM immunizations for short- and long-term immunity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18440102     DOI: 10.1016/j.vaccine.2007.11.083

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

2.  Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.

Authors:  Pooja Ralli-Jain; Delia Tifrea; Chunmei Cheng; Sukumar Pal; Luis M de la Maza
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

3.  Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.

Authors:  Jennifer R Carmichael; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-05-24       Impact factor: 3.641

4.  M cell-targeted ocular immunization: effect on immunoglobulins in tears, feces, and serum.

Authors:  Thomas E Phillips; Jeremy Sharp; Kay Rodgers; Hongshan Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-05       Impact factor: 4.799

Review 5.  Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.

Authors:  Thorsten Demberg; Marjorie Robert-Guroff
Journal:  Int Rev Immunol       Date:  2009       Impact factor: 5.311

6.  Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations.

Authors:  Anthony D Cristillo; Maria Grazia Ferrari; Lauren Hudacik; Brad Lewis; Lindsey Galmin; Britany Bowen; DeVon Thompson; Nikolai Petrovsky; Phillip Markham; Ranajit Pal
Journal:  J Gen Virol       Date:  2011-01       Impact factor: 3.891

7.  Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice.

Authors:  Griet A Van Roey; Mauricio A Arias; John S Tregoning; George Rowe; Robin J Shattock
Journal:  Eur J Immunol       Date:  2011-12-19       Impact factor: 5.532

8.  Comparative Safety and Efficacy Profile of a Novel Oil in Water Vaccine Adjuvant Comprising Vitamins A and E and a Catechin in Protective Anti-Influenza Immunity.

Authors:  Sapna Patel; Yasser Faraj; Debra K Duso; William W Reiley; Erik A Karlsson; Stacey Schultz-Cherry; Michael Vajdy
Journal:  Nutrients       Date:  2017-05-21       Impact factor: 5.717

9.  Optimization of mucosal responses after intramuscular immunization with integrase defective lentiviral vector.

Authors:  Alessandra Rossi; Zuleika Michelini; Pasqualina Leone; Martina Borghi; Maria Blasi; Roberta Bona; Massimo Spada; Felicia Grasso; Alessio Gugliotta; Mary E Klotman; Andrea Cara; Donatella Negri
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

10.  New prospects for a preventive HIV-1 vaccine.

Authors:  Jeffrey Brown; Jean-Louis Excler; Jerome H Kim
Journal:  J Virus Erad       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.